The guanine nucleotide releasing protein C3G was initially identi®ed as a Crk SH3-binding protein and recently shown to exhibit exchange activity on Rap1 proteins. Overexpression in NIH3T3 cells of a full-length C3G cDNA isolated from human placenta markedly reduced the focus forming activity of cotransfected, malignantly activated, ras oncogenes (5 ± 7-fold). C3G also had a reverting eect on sis-mediated transformation, decreasing the number of c-sis-induced foci by a factor of 5 ± 10-fold. The observed inhibitory eect of C3G on focus-forming activity of Ras and Sis was always higher than that observed with Rap1A, a known target of C3G. The inhibition of focus formation observed in the presence of C3G was not due to toxic eects on cell viability, since transfected C3G cells exhibited the same survival and growth rates as untransfected NIH3T3 cells or cells transfected with plasmid vector alone. Surprisingly, as opposed to Rap1A, which has no eect on Raf-1 oncogene-mediated transformation, C3G also reduced dramatically (6 ± 8-fold) the number of v-raf-induced foci in transfected NIH3T3 cells. The inhibitory eect on Raf-induced transformation suggests that C3G has other functional targets in addition to Rap1. A C3G mutant (C3G DCat) lacking the catalytic domain (CDC25-H) but retaining the rest of the N-terminal sequences, including the Crkbinding domain, exhibited similar ability than full length C3G to inhibit focus formation. In contrast, a C3G mutant (C3G Cat), containing the catalytic domain only but lacking the rest of the N-terminal sequences, did not have any inhibitory eect on transformation mediated by the oncogenes tested. The C3G-derived gene products overexpressed in our transfected cell lines localized to the cytoplasm and did not change the basal MAPK or JNK activity of those cell lines nor their ability to activate the kinases in response to agonists. Our results suggest that the N-terminal region of C3G, and not its catalytic domain, may be responsible for the inhibitory eects observed.
Introduction
Genetic and biochemical evidences from yeast, fruit ies and mammalian cells have uncovered the existence of distinct guanine nucleotide exchange factors (GEF) responsible for activation of Ras proteins by means of GDP/GTP exchange (reviewed in Boguski and McCormick, 1993; Lowy and Willmunsen, 1993; Feig, 1994) . Analysis of the primary structure of the major mammalian rasGEFs, including GRF1 (Shou et al., 1992) and GRF2 (Chen et al., 1993; Fam et al., 1997a,b) as well as Sos1 and Sos2 Bowtell et al., 1992) , reveals a linear modular structure composed of conserved, separate, domains including the catalytic region (CDC25-H domain; Boguski and McCormick, 1993) , the contiguous Dbl homology-(DH; Boguski and McCormick, 1993) and pleckstrin homology-(PH; Musacchio et al., 1993; Gibson et al., 1994) domains and a conserved domain located N-terminally to the CDC25-H region, designated REM (Fam et al., 1997a) which was initially thought to participate in Rasbinding (Lai et al., 1993) but whose real function remains unknown. In addition to those domains, the Sos family of exchangers contain also proline rich motifs located in their carboxy-terminus that interact with the SH3 domains of Grb2 Li et al., 1993; Rozakis-Adcock et al., 1993) and, to a lesser extent, Crk (Feller et al., 1995; Matsuda et al., 1992) .
The C3G gene product, originally identi®ed as a Crk-binding protein (Tanaka et al., 1994) , exhibits signi®cant structural homology in its carboxy-terminus with the catalytic domain of the Grf and Sos families of Ras GEFs. Thus, the C-terminal region of C3G contains a CDC25-H domain homologous to the catalytic domains of CDC25 and Sos family of proteins (Bon®ni et al., 1992; Bowtell et al., 1992; Cen et al., 1992; Martegani et al., 1992; Shou et al., 1992) and posesses also a region with homology to the REM domain. In addition, the central portion of C3G shares with Sos the presence of multiple proline-rich domains able to bind to the Crk SH3 domain (Knudsen et al., 1994; Tanaka et al., 1994) .
It has been proposed that Sos activates Ras through a Grb2/Sos complex that is recruited from the cytosol to the membrane (Buday and Downward 1993; Egan et al., 1993; Gale et al., 1993; Li et al., 1993; RozakisAdcock et al., 1993) . Genetic and biochemical studies revealed that both CDC25 and CDC25 Mm , its mammalian counterpart, are also able to activate Ras (Broek et al., 1987; Cen et al., 1992; Jacquet et al., 1992; Shou et al., 1992) . It has been recently reported that muscarinic receptors activate Ras through phosphorylation of Ras-GRF (Mattingly and Macara, 1996) . A closely related gene, designated GRF2, has also been identi®ed (Chen et al., 1993; Fam et al., 1997a,b) .
Although the biochemical properties of C3G have not yet been fully characterized, it has been shown that C3G is an activator for Rap1/smgp21/Krev-1 (Gotoh et al., 1995) . Rap1A is closely related to Ras in structure, and can inhibit transformation mediated by Ki-Ras (probably by competing for a common downstream eector), but not by the Raf-1 kinase (Sakoda et al., 1992) . Expression of transfected, membrane-targeted CAAX-C3G construct has a similar revertant eect on Ras, presumably through the activation of endogenous Rap1 (Gotoh et al., 1995) . Recent reports suggest that C3G may be required for expression of the full transforming activity of the v-Crk oncogene (Tanaka et al., 1997) and for R-ras activation in some tissues (Gotoh et al., 1997) .
Because of the similarities between C3G and the Ras exchange factors GRF and SOS, we were interested in analysing C3G structural and functional properties. For that purpose we cloned full-length C3G cDNAs (and derivatives thereof) from a human placenta library and analysed their functional eect in cotransfection experiments with either Ras, Sis or Raf oncogenes. Surprisingly, whereas Rap1 only has revertant eect on Ras and Sis focus-forming ability, overexpression of C3G in NIH3T3 also reduced the focus forming activity of Raf-1 kinase. We also determined the C3G region responsible for the reversion eect. Our results indicate that C3G may down-regulate Ras signaling through activation of Rap1, but it must also operate through dierent downstream target(s) which interact with regions other than the C3G catalytic domain.
Results
Cloning and characterization of C3G cDNA from human placenta A set of speci®c, PCR ampli®ed, cDNA fragments were used as probes to screen a human placenta cDNA library for C3G cDNA clones. Three representative, partial, cDNAs corresponding, respectively, to the 5', central and 3' regions of C3G were joined together to generate a full length, 3.2 kb, C3G clone. Sequence analysis indicated that our C3G clones were identical to that previously described by Tanaka et al., (1994) , except for their 5' end, which coded for the amino acid sequence M-S-G-K-I-E-K-A, instead of the M-D-T sequence described for the Tanaka et al. clone ( Figure  1) .
The sequence diversity found at the 5' end suggested that dierent C3G isoforms may exist, as was recently described for the Ras-speci®c Grf1 and Sos1 GEFs (Guerrero et al., 1996) . To determine whether this was the case, we examined the expression of C3G mRNA in human adult and fetal tissues using three separate probes, corresponding to the 5'-end (n244 ± n431), central (n1171 ± n1757) and 3'-end (n2193 ± n3111) portions of C3G (probes A, B and C, Figure 1) . A transcript about 7.5 kbp in size was detected in all cases, although at dierent levels of expression in dierent tissues. Thus, placenta, heart and muscle expressed markedly higher levels, whereas lung and liver expressed lower levels in comparison with other tissues (Figure 2a ). These results are in agreement with those of Tanaka et al. (1994) , who detected an ubiquitous 7.5 kbp transcript using the entire C3G gene as a probe. However, in addition to that band, our 3' end C probe allowed the detection of signi®cant levels of a shorter 4 kb transcript present in skeletal muscle and heart (Figure 2a ). This shorter transcript was also detected with the other two probes (A and B, Figure 1 ), but with lower intensity than the full length, 7.5 kb transcript. In agreement with these results immunoblot analysis of various human tissue extracts using speci®c anti C3G antibodies (Figure 2b ) demonstrated the ubiquitous expression of C3G-related protein products in all tissues analysed and con®rmed the existence in heart and skeletal muscle of an abundant, short C3G protein form (relative mobility, *40 kDa) recognized speci®cally by anti-C3G antibodies which paralleled the presence of the shorter transcripts detected in those two particular tissues.
Overexpression of transfected C3G in NIH3T3 ®broblasts
In an eort to ascertain the cellular functional role(s) of C3G, we set out to analyse the properties of NIH3T3 cells overexpressing transfected C3G genes. The full length C3G gene and its derivatives (Figure 1 ) tested here by transfection were cloned into vector pLTR2 (Di Fiore et al., 1987) , rendering the transfected cells resistant to killer HAT/gpt. The C3G constructs were transfected alone or in combination with Neo-selectable constructs coding for various oncogenes, as appropriate. Transfectants were then selected with either G418, HAT/gpt, or both, according to conditions of transfection.
Analysis of multiple, independent, transfections showed that the number of transfected, markerselected, NIH3T3 colonies obtained in transfections done with pLTR2-C3G constructs was not signi®cantly dierent than the number of selected colonies obtained Fam et al., 1997a) and a catalytic domain (CDC25-H) highly homologous to that of other members of the CDC25-family of Ras-GEFs. Probes used in expression studies, corresponding to the 5' (A; n244 ± n431), middle (B; n1171 ± n1757) and C-terminal (C; n2193 ± n3111) regions of C3G (Tanaka et al., 1994) are indicated. Full-length C3G and mutants C3G Cat and C3G DCat were cloned into mammalian expression vector pLTR2 (Di Fiore et al., 1987) . C3G DN (continuous line) was expressed in bacteria as a GST fusion (see Materials and methods) and used to generate rabbit anteserum #1008 in transfections with the vector pLTR2 alone. These observations indicated that overexpression of the transfected C3G gene had not toxic eect on NIH3T3 cells and, therefore, did not signi®cantly aect the survival rate and cell viability after transfection of NIH3T3 cells.
The levels of C3G protein expressed in transfectants (either marker-selected mass cultures or individual clones isolated by cloning cylinder) were measured by means of Western blot analysis with a commercial antiC3G polyclonal antibody raised against the last 19 amino acids of the C3G protein (see Material and methods) (Figure 3a) . A broad range of expression Figure 1) (Figure 3a) , ranging from about 1.5 to up to eightfold overexpression (determined by PhosphoImager analysis) over the level of endogenous C3G expressed in cells transfected with vector alone. The fact that C3G overexpression is not toxic for the transfected cells was con®rmed by the observation that the rate of proliferation of the C3G transfectants appeared to be independent of the levels of C3G expressed. Cell proliferation assays done with several representative clones expressing C3G showed similar growth rates in all cases, actually comparable to the growth rate of cells transfected with vector pLTR2 (Figure 3b ).
C3G decreases the focus-forming activity of cotransfected Ras oncogenes
It was shown recently that C3G can act as a guanine nucleotide exchange factor for Rap1 (Gotoh et al., 1995) , a Ras-related, small GTPase, able to reverse Ras-induced transformation of NIH3T3 (Kitayama et al., 1989; . To determine whether C3G could mimic the ability of its Rap1A target to reverse Ras transformation, we cotransfected NIH3T3 cells with a full-length C3G gene cloned in the mammalian expression vector pLTR2 (Di Fiore et al., 1987) and a pMEXneo construct expressing a transforming Ras(K12) oncogene (Benito et al., 1991) . We observed in several independent experiments that C3G cotransfection resulted in a signi®cant decrease (about 5 ± 7-fold) in the number of Ras-induced foci (Figure 4a,b) . These results con®rmed that C3G, like Rap1, is able to downregulate the transforming ability of Ras oncogenes. However, the inhibitory eect of C3G on Ras transformation was always bigger than that observed with Rap1A in parallel control experiments cotransfecting Rap1A and Ras oncogenes. Under similar experimental conditions, and in agreement with previous reports (Sakoda et al., 1992) we consistently obtained only a 2 ± 3-fold reduction in the number of Ras-induced foci (data not shown).
Analysis of the expression levels of C3G and Ras proteins in double-selected (gpt+neo) cotransfectants allowed to detect a wide range of expression levels for each of the cotransfected genes ( Figure 4c ). Whereas some clones expressed high levels of both gene Cotransfected C3G decreases the number of Sis-induced foci in NIH3T3
Using transient transfection assays it was reported previously that Rap1A is able to inhibit PDGFtriggered signals able to stimulate the c-fos promoter/ enhancer through the action of Ras (Sakoda et al., 1992) . We wished to check here the eect of C3G and Rap1A on c-Sis induced-transformation using permanent, double-selected cotransfections. Our results showed that both C3G and Rap1A were able to inhibit the focus-forming activity of cotransfected normal c-Sis, (Figure 5a,b) . As with the Ras cotransfections, we also observed consistently that C3G produced always a bigger reduction in the number of Sis-induced foci (5 ± 10-fold) than Rap1A (which only produced a 2 ± 3-fold decrease, not shown).
As opposed to Rap1A, cotransfected C3G decreases the number of v-raf-induced transformed foci
Consistent with the notion of a direct competition between cotransfected Ras and Rap1 for a common downstream eector, it is well established that, whereas Rap1 is able to antagonize the eects of Ras and other upstream signaling molecules, it is not able to block action of downstream Ras targets, such as Raf 1 (Sakoda et al., 1992) . In contrast to such behavior of Rap1A, it was striking to observe that cotransfection of NIH3T3 cells with both C3G and v-raf-oncogene, resulted in a signi®cant, C3G-dependent, decrease in the number of v-raf-induced transformed foci ( Figure  6a,b) . The magnitude of the C3G-dependent inhibition of Raf-induced foci (6 ± 8-fold) was similar, or even bigger, than the reduction of Ras-and Sis-induced foci described above (Figures 4 and 5 ). This observation suggested that, at least in the case of v-raf cotransfection, C3G may be causing the reduction in the number of transformed foci through interaction with other cellular targets dierent from Rap1.
Mapping of the region responsible for reversion of transformation. The inhibitory activity of C3G does not require its catalytic (CDC25-H) domain
To further characterize the C3G region responsible for the transformation-reverting eect of C3G, we constructed and tested deletion mutants lacking speci®c domains of the C3G protein ( Figure 1) . One of the constructs tested, designated C3G DCat, contained all C3G coding sequences except the C-terminal CDC25-H domain, containing the putative catalytic domain, highly homologous to those of other Ras GEFs such as Sos and Grf (Figure 1 ). We also analysed an additional construct, designated C3GCat, containing exclusively the sequences (1.5 kbp) coding for the conserved catalytic domain and its 5' adjacent REM domain, also conserved in all Ras GEFs. All these mutants were ®tted with a starting ATG codon and Kozak sequences and were cloned into pLTR2 for use in cotransfection experiments (see Materials and methods). Results obtained with C3G DCat are included in Figures 4 ± 6 and those obtained with construct C3G Cat are depicted in Figure 7 . Strikingly, cotransfection experiments involving the pLTR2 C3G DCat construct and each of the oncogenes Ras, c-Sis and v-Raf showed that this deletion mutant was as active, if not more, as full-length C3G in reducing the number of transformed foci produced by the oncogenes in the cotransfections (Figures 4 ±  6a,b) . Expression in the tranfectants of the C3G DCat protein (not recognizable by the commercial C3G antibody used in Figure 4c ) was monitored by Western blot (Figure 4d ) using rabbit antiserum #1008, raised against a bacterially-expressed GST fusion protein (see Figure 1 and Materials and methods). As with full-length C3G (Figure 4c ), transfected C3G DCat was expressed at various levels in the transfectants, and there was no observable direct correlation between the levels of expression of the oncogenes and the C3G mutant forms in the individual cotransfectants (Figure 4d ). These results strongly suggested that a function of C3G as a guanine nucleotide exchange factor is not required for the observed reversion of transformation. The notion that the GEF activity of C3G does not mediate its inhibitory eect on focus forming activity of various oncogenes was further con®rmed by functional analysis of the mutant C3G form encompassing the catalytic domain only (Figure 7) . Thus, cotransfection of the pLTR2 construct of mutant C3G Cat with either Ras, Sis or Raf oncogenes showed that this construct did not reduce the number of transformed foci produced by the oncogenes (Figure  7a) . Expression of C3G Cat in the transfectants was detected by immunoprecipitation and Western blot using the anti C3G antibody directed against the 19 Cterminal amino acids of the protein (Figure 7b ). Our observations indicate that the mutant C3G Cat, containing exclusively the catalytic region of C3G, did not display the same inhibitory eect on Ras, Sis or Raf transforming activity displayed by the mutant C3G DCat form, lacking that region but containing all other C3G coding sequences. These results indicate that the functional contribution of the CDC25-H region is not needed for the inhibitory eect.
Intracellular location of transfected gene products and biochemical characterization of the transfectants
In contrast to our observations with the C3G Cat transfectants, it was previously reported that a plasma membrane-targeted construct (encompassing the catalytic domain of C3G fused to a CAAX box) was able to weakly revert Ras-induced transformation (Gotoh et al., 1995) . To determine whether such forced cellular location might account for the dierent results observed, we analysed the intracellular location of the overexpressed, C3G-derived, gene products present in our transfectants. Immuno¯uorescence assays ( Figure  8 ) using antibody #1008, capable of equally recognizing full-length C3G as well as the C3G DCat and C3G Cat gene products, demonstrated that both the endogenous and the transfected, overexpressed; C3G gene products are located naturally to the cytoplasm and not to the plasma membrane. As shown in Figure 8 , we always observed a cytoplasmic, perinuclear location of C3G-related gene products in all of our transfectants, including cells transfected with empty pLTR2 vector (expressing only endogenous, native C3G; panel a) as well as cells overexpressing transfected, full-length C3G (panel b) or the shortened C3G DCat (panel c) or C3G Cat (panel d) forms. The absence of C3G-related gene products from the plasma membrane was con®rmed by Western immunoblot analysis (not shown) or subcellular fractions (S100 and P100) from the same transfected cell lines, which consistently showed a partition of the C3G-related gene products recognized by antiC3G antibodies, to the supernatant S100 fraction. These results strongly indicate that the native location of C3G gene products is cytoplasmic and that such subcellular distribution is probably linked to their speci®c function in suppression of transformation. We showed above that both full-length C3G and C3G DCat gene products are able to suppress transformation mediated by the Sis, Ras and Raf oncogenes. It is also known that those oncogenes trigger activation of cellular MAPK signaling pathways, and a recent report has suggested a role for C3G in v-Crk -induced activation of Jun kinase (Tanaka et al., 1997) . Therefore, in order to obtain some mechanistic insight into the process of suppression of transformation observed in our study, we decided to analyse those kinase activities in our transfectants. Figure 9 shows representative results measuring basal and stimulated levels of MAPK and JNK activity in stable transfectants overexpressing C3G and C3G DCat, alone or in conjunction with an activated Ras(K12) oncogene. Interestingly, we observed that overexpression of C3G and C3G DCat did not result in modi®cation of MAPK or JNK basal activities, nor in alteration of the ability of the transfected cells to respond to serum or TNFa, respectively, by activating those kinases (Figure 9 ). Similar results (not shown) were also obtained when those kinase activities were measured in anti-HA immunoprecipitates from cell lysates of transient transfectants where HA-tagged forms of MAPK and JNK were cotransfected with the same C3G and C3G DCat constructs. These results suggest that pathways other than MAPK or JNK activation may be involved in the mechanism of suppression of transformation by C3G and C3G DCat observed in our study.
Discussion
We cloned and functionally analysed a complete C3G cDNA clone from human placenta whose N-terminal amino acid sequence diered slightly from that of the original clone described by Tanaka et al. (1994) , suggesting that alternative splicing may play a role in the expression of this gene. Northern analysis using three separate probes spanning, respectively, the 5', central and 3' regions of the gene, revealed a major, ubiquitously expressed, 7.5 kb transcript, in agreement with previous reports (Tanaka et al., 1994) . However, in addition to that majoritary message, we detected also a novel second transcript, about 4 kb in size, expressed mostly in skeletal muscle and heart, thus reinforcing the possibility of the existence of alternatively spliced C3G forms, as suggested by our initial detection of a coding variant at the 5' end.
Using cotransfection in NIH3T3 cells we observed that expression of an exogenous, transfected full length C3G protein resulted in signi®cant inhibition of the number of transformed foci induced by cotransfected Ras, Sis and v-Raf. On ®rst analysis, the observed inhibition of Ras-and Sis-induced transformation could be consistent with a recently described role (Gotoh et al., 1995) of C3G as a guanine nucleotide exchanger for Rap1A, a small GTPase able to block the transforming activity of Ras and other upstream oncogenes (Sakoda et al., 1992; Cook et al., 1993) . However, it is well documented that Rap1A does not have the ability to block Raf function (Sakoda et al., 1992 ) and yet our cotransfection experiments clearly showed that C3G exhibited a similar, if not higher, ability to block Raf-induced transformation, as compared to Ras or Sis induced transformation. These results suggested that C3G may be exerting its action through functional interaction with other cellular targets dierent from Rap1.
In an eort to de®ne the structural domains within C3G responsible for the reduction of transforming activity, we generated deletion mutants aecting the conserved catalytic domain responsible for the activation of Rap1 through its guanine nucleotide exchange activity. We observed that mutant C3G DCat, lacking the CDC25-homology region, had the same behavior than full-length C3G regarding the inhibition of focus forming activity in cotransfection experiments. This indicated that the CDC25-homology region, corresponding to the catalytic region conserved in all the exchange factors for the Ras-family of GTP-binding proteins, is not critical for the reduction of focus formation mediated by cotransfected C3G. This notion was further con®rmed by the observation that the C3G Cat mutant (containing only the catalytic domain plus the REM region), did not show any inhibitory eect on Ras, Sis or Raf transforming activity. It should be noted that an isolated C3G Cat fragment similar to the one used here has been shown previously to be functional in complementation assays of Saccharomyces cerevisiae CDC25 mutants (Tanaka et al., 1994) . Structural/functional analysis of our results indicated that all C3G constructs displaying an inhibitory eect on transformation have in common the presence of the Crk-binding region, suggesting that this region is involved in mediating the anti-transforming properties of C3G.
Our observation that the catalytic portion of C3G alone had no inhibitory eect on the Ras, Sis and Raf focus-forming activity is in apparent disagreement with a previous report (Gotoh et al., 1995) showing a revertant eect on DT cells (a v-Ki-ras transformed NIH3T3 cell line) by the catalytic domain of C3G. However, it should be mentioned that, in that report, C3G or C3G Cat could only revert the transformed phenotype of DT cells when containing a CAAX box in the C terminus. In our experiments, neither fulllength C3G nor the mutant C3G DCat needed to be farnesylated to inhibit the transforming activity of Ras, Sis or Raf. Indeed, immuno¯uorescence analysis and subcellular fractionation of control NIH3T3 cells and cells overexpressing the various C3G constructs transfected in our study con®rmed that both the native and the transfected C3G-related gene products display a cytoplasmic, perinuclear localization. It appears, therefore, that the abnormal subcellular location of the plasma membrane-targeted C3G-CAAX constructs used by Gotoh et al. (1995) may account for the diering results reported. Biochemical analysis of our transfectants indicated also that neither MAPK nor JNK appear to be involved in the transformation suppression ability of C3G and C3G DCat. We observed that overexpression of those constructs in the transfectants did not result in modi®cation of their basal MAPK and JNK activity, nor in alteration of the ability of the transfected cells to activate those kinases in response to outside agonists. These observations strongly suggest that C3G activates pathways other than MAPK or JNK activation in the process of suppression of transformation described here. This notion is not necessarily in disagreement with the fact that oncogenes whose transforming ability is suppressed by C3G, such as Ras and Raf, are known proximal activators of MAPK signaling pathways, nor with a recent report indicating that C3G may mediate JNK activation by the oncogene v-Crk (Tanaka et al, 1997) . In fact, it has also been reported that although Ras is required for v-Crk transformation, the contribution of Ras eector(s) other than MAPK appears to be needed for such transformation process (Greulich and Hanafusa, 1996) . Furthermore, in complete agreement with our observations, the report by Tanaka et al. (1997) described that whereas coexpression of C3G and v-Crk enhanced the JNK activity of v-Crk NIH3T3 cells, expression of C3G alone had no eect on the JNK activity and growth properties of these cells.
The results presented in this paper suggest that C3G gene products may exert dierent cellular eects, each mediated by distinct, speci®c, domains within the fulllength C3G protein. Thus, (i) on one hand, C3G has been reported to act as an exchange factor and activator for cellular Rap1 and R-Ras (Gotoh et al, 1995 (Gotoh et al, , 1997 , an action mediated through the enzymatic activity of its conserved CDC25-H catalytic domain. The functional roles of Rap1 and R-Ras are not clear. Rap1 has been reported to be very abundant in human neutrophil membranes and to copurify with a component of the NADPH oxidase complex of human phagocytes and B lymphocytes (Quinn et al., 1989) . It has also been suggested that Ral-GDS may be an eector of Rap1A (Herrmann et al., 1996) , thus providing a link between Rap1A, JNK and cytoskeleton events. Roles for R-Ras have been proposed in control of cellular proliferation (Saez et al., 1994; Cox et al., 1994) , apoptosis (Wang et al, 1995) and cell adhesion (Zhang et al., 1996) . (ii) On the other hand, C3G is able to bind speci®cally to Crk through its central region. It is unknown which upstream and downstream signals may be associated with the C3G-Crk interaction. In any event, it appears that the Crkbinding domain is actively involved in the reversion of transformation described in this report. Further studies are needed to clarify which signaling pathways are aected by cellular C3G gene products and how the eects of each of its domains are integrated in the context of the overall control of cellular proliferation and development.
Materials and methods

cDNA library screening
Overlapping C3G cDNAs were isolated by screening a commercial human placenta cDNA library (Stratagene), made in vector pBluescript SK + , with two 32 P-labeled (random-priming; Stratagene) cDNA probes (A and B, Figure 1 ). The probes were previously obtained by PCR screening of human placenta (Clontech) and B5/589 cell line cDNAs, using oligonucleotides corresponding to positions n244 ± n268/n401 ± n430 (probe A), and n1171 ± n1206/n2193 ± n2222 (probe B). Three overlapping cDNA clones were joined together to generate a full-length C3G gene. The resulting construct, named pSKC3G18, contains 3248 bp corresponding to the complete C3G coding sequences plus 490 additional, non-coding, nucleotides located at the 3' end.
Construction of C3G mammalian expression vectors
The full-length C3G cDNA was cloned as a 3.2 kb BamHI fragment into the BamHI site of plasmid pLTR2. This plasmid contains 3 kb of MoMuLV sequences including 5' and 3' LTR'S, ampicillin-and gpt-resistance genes (Di Fiore et al., 1987) . The construct obtained was named pLTR2C3G.
A C3G mutant lacking the catalytic domain was constructed by deleting a MscI ± BamHI fragment, corresponding to the last 457 bp of the full length C3G cDNA present in plasmid pSKC3G18. After ligating a NheI stop linker to the 3' end of the deleted fragment (designated C3G DCat), the resulting fragment was subcloned between sites BamHI and KpnI of vector pSP72 (Promega). The C3G DCat insert of the above plasmid was then cloned into pLTR2, as a 2.7 kb BamHI ± ClaI fragment. This construct was named pLTR2 C3G DCat.
A mammalian expression vector driving expression of a construct spanning only the catalytic region of C3G was also generated. Thus, to generate plasmid pLTR2C3G Cat (Figure  1 ), an AccI (n1766) ± XhoI (n3262) fragment from plasmid pSKC3G18, carrying both the REM domain (Fam et al., 1997a) and the neighboring catalytic region (CDC25-H), was ®rst subcloned into plasmid pSP72 (Promega). The fragment was then subcloned, as a BamHI insert, into pCEVKZ (Miki et al., 1989) and ®nally introduced into pLTR2 as a XhoI ± BglII fragment containing the Kozak sequence and ATG from plasmid pCEVKZ, in frame with the insert.
Northern blot analysis
Northern blots containing 2 mg per lane of polyadenylated RNA (Clontech) isolated from various adult and fetal human tissues were hybridized with probes spanning the dierent coding regions of hC3G (probes A, B and C, Figure 1 ). The cDNA probes were 32 P-labeled by random priming (Stratagene) and used under high stringency hybridization conditions at 428C in the presence of 50% (vol/vol) formamide, 56SSPE (16SSPE=150 mM NaCl/ 10 mM sodium phosphate, pH 7.4/1 mM EDTA), 100 mg/ ml herring testes DNA, 1% SDS, and 56Denhardt's solution. After 24 ± 36 h of hybridization, the membranes were washed three times in 0.16SSC/0.1% SDS at 508C and autoradiographed at 7708C in the presence of intensifying screens. An actin probe was used to normalize hybridization signals.
Cell culture conditions and permanent transfections NIH3T3 cells were transfected by the calcium phosphate method (Chen and Okayama, 1987) using thymus DNA (Boehringer-Mannheim, Cat #104 ± 167) as carrier. Following 18 ± 20 h incubation at 378C and 5% CO 2 , cells were washed with 5 ml of DMEM containing 10% calf serum (Colorado Serum Co.). After 1 h incubation, the culture medium was replaced with 10 ml of 5% serum DMEM and cells were incubated further for 24 h. After that time period, transfectants were selected, as appropriate, in the presence of either 750 mg/ml geneticin (G418), killer HAT medium (250 mg/ml xanthine, 25 mg/ml mycophenolic acid, 16HAT salt solution in 10% serum DMEM), or both. Cells were fed twice per week until selection was completed. Focus-forming activity was also quantitated by counting numbers of morphologically transformed foci present in non selected, stained, cultures. Individual colonies of transfected and marker-selected cells were isolated using cloning cylinders, and the resulting cell lines were propagated in DMEM-10% calf serum supplemented with the appropriate selection markers in each case.
DNAs used in the transfections included the gpt-selectable C3G constructs metioned above (pLTR2-derived constructs expressing C3G, C3GDCat and C3G Cat), as well as neoselectable mammalian expression constructs coding for H-ras (K12) (pMEXneo H-ras lys12 , Benito et al., 1991) , v-raf (plasmid EH-rafneo, a LTR derived construct, Cuadrado et al., 1993) and c-sis (pMMTneo-sis, LaRochelle et al., 1990) . Plasmids pLTR2 (Di Fiore et al., 1987) and pMEXneo (Benito et al., 1991) were used as empty vector controls in all transfection experiments.
Cell extract preparation for the analysis of C3G and ras expression
Total cellular protein extracts from transfected NIH3T3 clones were obtained by lysis of cell cultures (1 ml per plate) with RIPA buer (10 mM Tris-HCl pH 7.5, 100 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with protease and phosphatase inhibitors (25 mg/ml aprotinin, 25 mg/ml leupeptin, 1 mM PMSF, 2 mM Na 2 VO 4 ). Protein concentration in clear lysate supernatants was determined using the BCA protein assay reagent A (Pierce).
Antibodies and immunological analysis
AntiC3G polyclonal antibody, directed against the last 19 amino acids of the protein, was obtained from Santa Cruz Biotechnologies (SC-869). We also used an antiC3G antiserum (#1008) generated in our laboratory against a bacterially expressed C3G protein form encompassing both the Crk-binding region and the CDC25-H catalytic domain (Figure 1 ). This protein was puri®ed from E. coli bacteria harboring plasmid pGEXC3G DN, encoding a GST-fusion protein that contains a C3G fragment extending from amino acid 391 to the end of the protein (a.a. 1077). Plasmid pGEXC3G DN was constructed by inserting an EcoRI fragment of C3G c-DNA, spanning region n1171 ± n3248, into pGEX4T-1 (Pharmacia). Ras proteins were analysed in transfectants using, as indicated, rat monoclonal antibody Y13-259 (ATCC CRL1742) and mouse monoclonal antibody M90 (Lacal and Aaronson, 1986 ). Both antibodies were puri®ed by ammonium sulfate precipitation from hybridoma culture supernatants. Anti rat MAP kinase R2 polyclonal antibody was purchased from UBI (# 06-182) and anti JNK1 monoclonal antibody was obtained from Pharmigen (#15701A).
C3G immunoprecipitation from cell extracts was carried out by incubating 1 mg of protein extract in RIPA buer with 3 mg of antiC3G polyclonal antibody (SC-869) for 2 h at 48C. For competition experiments, the antibody was previously incubated with the control peptide (15 mg) for 15 min at 48C and then added to the lysates. 100 ml of 50% Gammabind G sepharose beads (Pharmacia), washed in RIPA buer without inhibitors and precoated in RIPA supplemented with 1 mg/ml BSA, were added to each sample and incubated further for 2 h. The immune complexes were collected by centrifugation at 14 000 g and rinsed three times in RIPA buer before electrophoretic analysis.
For Ras immunoprecipitations, clear lysates (500 mg of protein in RIPA buer) were incubated with 1.5 mg of rat anti-Ras Y13-259 monoclonal antibody for 2 h at 48C. Simultaneously, 100 ml of 50% Gammabind G sepharose beads in RIPA plus 1 mg/ml BSA were coated with rabbit anti-rat antibody (1 : 100). Both mixtures were then combined and incubated further for 2 h at 48C, with shaking. The immuno complexes were rinsed three times in RIPA buer.
For Western blot analysis, cell lysates (100 mg/lane) or immunoprecipitates were loaded onto 10% (for analysis of C3G), 14% (for analysis of Ras expression) or 10 ± 18% (for analysis of MAPK and JNK) SDS-polyacrylamide gels and the proteins transferred to PVDF membranes (Millipore Immobilon-P) by electroblotting. C3G expression in human tissues was analysed using commercial Multiple Tissue Western (MTW) Blots (7721-1, Clontech Laboratories Inc.) containing various human tissues extracts (75 mg total protein per lane). Membranes blocked in TTBS (10 mM Tris-HCl, pH 7.4, 0.9% NaCl, 0.05% Tween 20) plus 3% non-fat milk were incubated with puri®ed polyclonal antiC3G antibody (1 mg/ml), mouse monoclonal antiRas M90 antibody (2 mg/ ml), antiJNK antibody (1 mg/ml) or anti-Rat MAP kinase R2 antibody (1 mg/ml) as indicated, and then developed with 125 I proteinA (0.1 mC/ml; 0.1 mg/ml) or ECL (Amersham), as indicated. After extensive washing in TTBS, immunoblots were autoradiographed and exposed in the presence of intensifying screens or incubated with the appropriate HPL second antibody and developed with the ECL kit. The speci®city of the signals was con®rmed in parallel negative controls where the immunoblots were stripped of any remaining signal and then reanalysed by the same methodology using primary antibody mixtures that had been preincubated for 30 min at 48C in the presence of an excess (20 ± 40 mg) of the corresponding immunizing peptide or protein.
Immuno¯uorescence assays were done essentially as described (Jackman et al., 1995) . Cell cultures grown on 8-well LabTec glass chamber slides (Nunc, Inc.) were ®xed with 4% formaldehyde, washed twice with cold PBS, permeabilized with 0.2% Triton X-100, washed again with PBS and blocked with goat heat-inactivated serum. Preparations were then treated with anti-C3G antiserum #1008 (1 mg/ml) as primary antibody and Cy3 conjugated anity pure Goat anti-Rabbit IgG (Jackson immunoResearch Laboratories Inc) (3 mg/ml) as secondary antibody. The slides were viewed through an Axiovert 135 TV microscope. Photographs were taken with a Hamamatsu XC77 digital camera and processed using the IPLab Spectrum program (Signal Analytics Corporation).
Kinase assays in cell lysates
Serum-starved, subcon¯uent cultures of the indicated cell lines were left untreated or stimulated with either serum (20%, 20 min) or TNFa (10 ng/ml, 15 min) before extensive washing with cold PBS and lysing at 48C in hypotonic buer containing 20 mM HEPES pH 7.5, 2.5 mM MgCl 2 , 10 mM EGTA, 1% NP-40, 1 mM DTT, 40 mM b-glycerophosphate, 2 mM sodium vanadate, 20 mg/ ml leupeptin and 1 mM AEBSF.
MAPK assays were performed essentially as described (Erikson and Maller, 1989) . Brie¯y, 1 mg of each lysate was diluted in 40 ml of a kinase assay mixture containing: 20 mM HEPES (pH 7.3), 1 mg/ml MBP (Sigma), 10 mM MgCl 2 50 mM ATP and 0.12 mCi/ml [g-32 P]ATP. After 10 min at 308C, the reaction was stopped by adding 10 ml of 46 Laemmli buer and heating at 958C for 5 min. Samples were analysed by means of 10 ± 18% gradient sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS ± PAGE) and autoradiography in the presence of intensifying screens. For comparison and normalization of samples, amount and mobility of p42 and p44 Erk protein bands in the lysates were also determined by immunoblotting with a commercial anti-rat MAP Kinase R2 (Erk1-CT) antibody (UBI).
For JNK assays, endogenous JNK was immunoprecipitated from equal amounts of cleared lysates by incubation with an speci®c antibody (Pharmigen) (2 mg antibody/1 mg lysate; 1 h, 48C). Immunocomplexes recovered on GammaBind Sepharose beads (Pharmacia) were washed three times with PBS containing 1% NP-40 and 2 mM sodium vanadate, once with 100 mM Tris (pH 7.5) containing 0.5 M LiCl, and once with kinase reaction buer containing 12.5 mM MOPS (pH 7.5), 12.5 mM b-glycerolphosphate, 7.5 mM MgCl 2 , 0.5 mM EGTA, 0.5 mM sodium¯uoride, 0.5 mM sodium vanadate. JNK activity assays of the immunoprecipitates were performed essentially as described (Coso et al., 1995) by resuspension in 30 ml of kinase reaction buer containing 1 mCi [g-32 P]ATP, 20 mM cold ATP and 3 mg of puri®ed, bacterially expressed, GST-cJun79 fusion protein as the substrate. After 30 min at 308C, reactions were terminated by addition of 10 ml of 46Laemmli buer and boiling for 4 min. Samples were analysed by SDS electrophoresis on 10 ± 18% gradient polycrylamide gels and autoradiography. For normalization, amount of JNK protein in the lysates was determined by means of immunoblotting using speci®c anti-JNK1 monoclonal antibodies (Pharmigen).
